Article Text

Download PDFPDF

Tumor control by intravenous administration of STING ligand requires combination with precisely timed radiation therapy
  1. Jason Baird1,
  2. David Friedman1,
  3. Benjamin Cottam1,
  4. Marka Crittenden2 and
  5. Michael Gough1
  1. Aff1 grid.415337.7Earle A. Chiles Research InstituteProvidence Cancer Center Portland OR USA
  2. Aff2 grid.420050.30000 0004 0455 9389Earle A. Chiles Research InstituteProvidence Cancer Center; The Oregon Clinic Portland OR USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

We have demonstrated that radiation alone is weakly effective at generating anti-tumor adaptive immune responses despite release of tumor-associated antigen. We hypothesized that providing potent adjuvant would improve this immune response increasing immune control of local and distant disease. Recently, we have shown that activation of STimulator of INterferon Genes (STING) innate signaling has the ability to propagate an adaptive immune response that is initiated in the tumor microenvironment (TME). Our experiments thus far have applied local administration of STING ligands to the tumor; however, this may not always be practical in patients. In the current work, we evaluated systemic administration of STING-ligand and found that unlike direct intratumoral administration, systemic administration was unable to control a selection of murine tumor models. However, combination with tumor targeted radiation therapy in these models resulted in tumor control by systemic STING-ligands. This effect was dependent on the precise timing of STING-ligand and tumor-targeted radiation. We propose that radiation therapy targets immune cells and inflammatory mechanisms activated by systemic STING-ligand to the tumor environment, resulting in therapeutic synergy.


Aduro Biotech, Inc., Berkeley, CA. provided some materials used.